HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2-HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherap...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Weitsman, Gregory, Barber, Paul R., Nguyen, Lan K., Lawler, Katherine, Patel, Gargi, Woodman, Natalie, Kelleher, Muireann T., Pinder, Sarah E., Rowley, Mark, Ellis, Paul A., Purushotham, Anand D., Coolen, Anthonius C., Kholodenko, Boris N., Vojnovic, Borivoj, Gillett, Cheryl, Ng, Tony
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239455/
https://ncbi.nlm.nih.gov/pubmed/27618787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9963
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items